Pediatric Rheumatology Online Journal

Abbreviations: major histocompatibility complex (MHC), juvenile idiopathic arthritis (JIA), T regulatory (Treg), human leukocyte antigen (HLA), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), heat shock protein (hsp), tumor necrosis factor alpha (TNFα), interleukin (IL)

Abstract

In order for the normal immune system to protect against foreign pathogens, it must be able to distinguish self from nonself. This is accomplished by a process of microbial pattern recognition in the innate immune system and by central and peripheral tolerance in the adaptive immune system. However, despite these mechanisms of tolerance, self-reactive T cells still exist and can cause autoimmune diseases via a number of mechanisms, including molecular mimicry, epitope spreading, and bystander activation. In this article we aim to explore the scientific data supporting these concepts of pathogenesis and how they can be applied to future therapies, such as epitope-specific immunotherapy which aims to induce tolerance with cross-reactive heat shock proteins conserved in both microbes and humans. Ultimately, the goal is to improve knowledge and understanding of the role of infectious pathogens in molecular mechanisms and genetic predispositions involved in autoimmune disease pathogenesis, so that more focused therapies can be developed.

Physiological Inflammation

The immune system exists to protect the host against foreign invaders. The normal host immune response, consisting of the innate and adaptive immune systems, elicits a powerful inflammatory response which is necessary to help control the spread of foreign pathogens. However, if left unchecked, this inflammatory response can lead to tissue destruction. The innate immune system, consisting of endothelial cells, phagocytes, natural killer cells, and antigen presenting cells such as macrophages and dendritic cells, responds to foreign invaders with an early inflammatory response by recognizing conserved regions on microbes. Despite its prompt response, innate immunity does not provide lasting memory.

In contrast, the adaptive immune system, consisting of T and B cells that are stimulated by cytokines and antigen presenting cells from the innate immune system, produces a targeted cell-mediated immune response with memory that can facilitate clearance of the same microbial invader in the future [[1]]. In order for the immune system to protect against foreign invaders, it must be able to distinguish self from nonself. This is the challenge that both the innate and adaptive immune systems face on a daily basis.

Self versus Nonself: The Innate Response

The first line of defense against a foreign antigen is the innate immune system. While this arm of the immune system cannot produce immunological memory, it does begin the inflammatory process that works towards eradication of the pathogen, in addition to activating the adaptive immune response. For example, macrophages have a mannose receptor that recognizes a sugar residue commonly found on microbes and not on host cells, which when bound can lead to phagocytosis of the microbe [[2]]. In addition, cells such as endothelial cells, macrophages, dendritic cells, and neutrophils contain transmembrane evolutionarily-conserved proteins known as Toll-like receptors that recognize microbial conserved molecular structures [[3],[4]]. These Toll-like receptors activate a transcription factor known as NF-κB, which subsequently leads to production of cytokines and co-stimulatory molecules on antigen presenting cells needed to initiate an adaptive immune response [[5]].

Self versus Nonself: Central and Peripheral T Cell Tolerance

Just as with the innate immune system, it is crucial to the host that cells in the adaptive immune response be able to differentiate self from nonself. For T cells, this is initially achieved at the thymic level by positive selection for those cells that weakly recognize self antigens bound to a major histocompatibility complex (MHC) on an antigen presenting cell [[6]]. In addition, T cells whose receptors bind too strongly to self antigens undergo cell death, a process known as negative selection [[7]]. These two forms of central selection strive to create a T cell repertoire that can respond to peptides bound to self MHC molecules while removing T cells that would lead to an autoimmune response.

But how does a T cell that will respond to a foreign antigen become positively selected in the thymus if only self antigens exist during thymic selection? One theory is that the host’s carefully selected T cells are crossreactive, recognizing both microbial and self epitopes, a mechanism known as molecular mimicry [[8],[9]]. A molecular basis for this crossreactivity is supported by the crystallography data showing large conformational changes in the T cell receptor upon antigen binding, therefore providing structural evidence that different peptides can bind to the same T cell receptor [[10]].

Recently it was shown in a non-transgenic mouse model that physiological positive selection can generate an oligoclonal population of T cells that recognize both self peptides and a bacterial homologue [[11]]. Such evidence supporting both the structural and physiological feasibility of molecular mimicry may explain how self antigens, the only antigens available during thymic development, are crucial in developing a normal T cell repertoire that can later respond to infectious agents.

Tolerance is not just an event that occurs in the neonatal period but one that must continue throughout life as we are faced daily with foreign antigens and the immune system must decide as to how strongly to respond to these antigens. Although negative selection in the thymus plays a major role in self tolerance, studies have shown that healthy individuals have self-reactive T cells in the periphery which have the potential for activation leading to autoimmune disease [[12]]. To decrease the probability of self-reactive T cells even further, tolerance occurs in the periphery via ignorance, deletion, or anergy.

In the case of ignorance, self antigens may be in such low doses that they do not trigger a T cell response or they may be sequestered and, therefore, are inaccessible to T cells [[13],[14]]. Deletion, also known as activation-induced cell death, occurs when the Fas protein, involved in the regulation of apoptosis, binds to its ligand on the surface of chronically stimulated T cells [[15]]. In one experiment, disruption of the signal cascade from the Fas-Fas ligand in a murine model led to defective activation-induced cell death, and consequently, autoimmune arthritis [[16]]. A third mechanism of peripheral T cell tolerance is encounter of a self-antigen leading to anergy. Originally thought to occur via lack of costimulation, it is now known that anergy requires in vivo ligation of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which inhibits activated T cells [[17]].

Peripheral tolerance can also be controlled by a distinct subset of T cells called regulatory T cells (Treg). Thymus-derived Tregcells which express both CD4 and CD25 surface markers were first shown to be important in peripheral tolerance when it was noted that inoculation of CD25⁺ T cells could prevent the development of autoimmune diseases seen in thymectomized neonatal mice [[18]]. One recent study showed a higher frequency of Treg cells in the synovial fluid of patients with a remitting form of oligoarticular JIA than in patients with extended oligoarticular JIA, which has a less favorable prognosis [[19]]. Another study has further identified that the functional T regulatory cells are more specifically CD4⁺CD25^brightcells, and can be found in the synovium of patient with rheumatoid arthritis [[20]]. These data appear to support the role of Tregcells in regulating inflammation, and consequently the severity of disease, in the target organ.

Mechanisms

Despite these methods of central and peripheral tolerance, self-reactive T cells which can be triggered to cause autoimmune diseases still exist. The mechanisms that have been found to show a link between infectious pathogens and autoimmune diseases include molecular mimicry, epitope spreading and bystander activation (Table 1).

Molecular mimicry

Molecular mimicry is the concept that T cells are activated that can recognize both microbial and self epitopes and an excessive inflammatory process occurs. One of the most studied autoimmune diseases occurring via molecular mimicry is the heart disease noted in rheumatic fever. Both animal and human studies have shown that exposure to the dominant epitope of group A streptococcal polysaccharide, N-acetyl-glucosamine, leads to cross-reactive T cells and antibodies to cardiac myosin [[21],[22],[23],[24],[25]]. Further data supporting molecular mimicry is seen in the development of herpes stromal keratitis after herpes simplex virus-type 1 infection. In this condition, T cell clones respond to both a corneal self antigen and a peptide derived from herpes simplex virus-type 1 [[26]]. Mutant herpes simplex virus-type 1 that lacks this epitope did not induce keratitis [[27]]. Type 1 diabetes, an autoimmune disease that results from the destruction of pancreatic islet β cells, has been associated with rotavirus and cytomegalovirus. These viruses share sequence homology to the autoantibody glutamic acid decarboxylase found commonly in type 1 diabetics [[28],[29]].

Another example of homology between a microbial peptide and self antigen is in inflammatory heart disease where the outer membrane of Chlamydia is homologous to the murine heart muscle myosin heavy chain. Immunization of a murine model with this homolog or infection with Chlamydia trachomatis via the respiratory tract led to a similar frequency of inflammatory heart disease as immunization with the myosin peptide [[30]]. Also in susceptible mouse strains expressing a particular MHC Class II molecule, immunization with myelin basic protein peptide can induce experimental autoimmune encephalomyelitis [[31]]. Supporting the role of molecular mimicry in this model is the fact that the herpes virus Saimiri peptide, which has limited homology to myelin basic protein, stimulates the myelin basic protein-specific T cell hybridomas and causes experimental autoimmune encephalomyelitis in mice [[32]].

As for the role of molecular mimicry in rheumatologic disorders, rheumatoid arthritis has shared epitopes between the human leukocyte antigen (HLA) -DRB1 chain found in 90% of patients and the dnaJ class of heat shock proteins in Escheria coli. While patients with early rheumatoid arthritis had proliferation of T cells with dnaJ peptide in vitro stimulation, normal subjects with the same HLA-DR type, identical twins without disease, and those with other autoimmune diseases did not [[33]]. In oligoarticular juvenile idiopathic arthritis (JIA), T cell cytotoxic responses and production of proinflammatory cytokines, such as interferon gamma, were elicited in vitro in response to stimulation with Epstein-Barr virus proteins homologus to 9-mer peptides derived from HLA Class II molecules associated with oligoarticular JIA [[34]].

With regard to juvenile dermatomyositis, patients noted to relapse after a Streptococcus pyogenes pharyngitis led to the hypothesis that recognition of streptococcal proteins might trigger an autoimmune response to a muscle antigen [[35]]. Further supporting the role of molecular mimicry in juvenile dermatomyositis, self epitopes in the human skeletal myosin heavy chain were found to be homologous to peptides in the Streptococcus pyogenes M5 protein [[36]]. In vitro studies with the human skeletal myosin heavy chain and its M5 peptide homologues showed more elevated cytotoxic T cell responses to the M5 peptide in children with active juvenile dermatomyositis than in patients in remission, children with JIA, patients with post-streptococcal disease (such as glomerulonephritis, rheumatic fever, and reactive arthritis) or healthy controls [[37],[38]]. In these same patients, production of tumor necrosis factor-alpha (TNF-a) was elevated in the peripheral blood mononuclear cells of patients with active juvenile dermatomyositis exposed to the M5 peptide compared to controls. Finally, this same study showed an overlap in the T cell receptor V_bregions recognizing the human skeletal myosin heavy chain peptide and the M5 peptide, further supporting the role of molecular mimicry in the pathogenesis of juvenile dermatomyositis.

Epitope spreading

Besides molecular mimicry, two other theories are commonly used to explain how infectious agents can lead to autoimmune diseases. The first of these two, known as epitope spreading, focuses on microbially-induced T cell-mediated tissue damage that leads to release of self antigens from a sequestered site [[39]]. These self peptides are then presented to T cells by local antigen presenting cells, spreading the immune response to self antigens. One such example is Theiler’s murine encephalomyelitis virus which induces a T cell-mediated demyelinating disease in mice that clinically resembles chronic, progressive multiple sclerosis [[40]]. Kinetic and functional studies showed that T cell responses to myelin occurred because of new priming of self-reactive T cells to sequested autoantigens from demyelination, rather than cross-reactivity, as occurs with molecular mimicry [[41]].

Bystander activation

Another alternative theory to molecular mimicry focuses on the effects of the microbially-induced inflammatory cascade rather than an antigen-specific response. This concept, known as bystander activation, is the nonspecific activation of self-reactive T cells stimulated by cytokines [[42],[43]]. Coxsackie B4 virus has been associated with the development of type 1 diabetes and shared sequence similarities with the islet autoantigen glutamic acid decarboxylase found in these patients. However, rather than finding viral acceleration of diabetes as would be expected in molecular mimicry, mice with a transgenic T cell receptor specific for a different islet autoantigen developed diabetes, reflecting T cell receptor-independent bystander activation [[44]].

While molecular mimicry, epitope spreading and bystander activation support the role of pathogens in autoimmune disorders, it is unclear why of the many individuals exposed to these common pathogens, only a relatively small percentage develop autoimmune diseases. In fact, though healthy humans are exposed to killed or live microbes via vaccines, no conclusive data exists linking vaccinations with autoimmune diseases [45]. Therefore, though a pathogen may be part of the initial trigger, it is likely that genetic predisposition and environmental exposures are also strongly involved.

Genetics and Environmental Factors in Autoimmunity

Diabetes

Among all genetic components, human leukocyte antigen (HLA) class II genotype has been the most closely associated genetic factor linked to autoimmune diseases. In type 1 diabetes, allelic variations of three adjacent class II genes, HLA-DRB1, -DQA1, and –DQB1, have been linked to an increased risk of developing disease [[45],[46]]. Furthermore, differences in worldwide patterns of incidence of type 1 diabetes can be partially explained by genetic allelic differences between different ethnic groups [[47]]. In a country such as Finland which has the world’s highest incidence of type 1 diabetes, the progression to diabetes in monozygotic twins was 50% within 7 years if the index twin was diagnosed at 10 years of age or younger [[48]]. In a study comparing North American monozygotic twins, the long-term risk of developing type 1 diabetes if the co-twin developed disease before 15 years of age was 44% [[49]]. The fact that disease penetrance was not 100% in these twins suggests that while genetic factors may play a substantial role in type 1 diabetes, nongenetic factors such as environment and the host’s immune response also influence the expression of autoimmune disease.

Environmental factors that have been implicated in the development of type 1 diabetes include coxsackie virus, where polymerase chain reaction analysis of sera from diabetic children showed that 43% were positive for coxsackie B virus, compared to 4% of controls [[50],[51]]. A similar correlation has been found between cytomegalovirus and type 1 diabetes, where 20% of patients had cytomegalovirus genomic DNA in their lymphocytes, compared to only 2% of controls [[52]]. In a murine model, infection with cytomegalovirus has also been shown to accelerate the onset of diabetes [[53]]. Besides viruses, chemicals such as alloxan and streptozotocin have been shown, at least in experimental animal models, to induce diabetes via cytotoxic action against pancreatic β cells mediated by reactive oxygen species [[54],[55]].

Rheumatic diseases

In rheumatologic disorders, genetic and environmental associations have also been found to be important in the development of autoimmune disorders. In JIA, certain HLA class II alleles, namely HLA-A2 (isn’t this a class I allele ??), HLA-DRB1*08, HLA-DRB1*11, and HLA-DPB1*02, are independently associated with increased risk of developing disease [[56],[57]]. Furthermore, when stimulated with Epstein-Barr virus-derived peptides homologous to self HLA epitopes, peripheral blood mononuclear cells from JIA patients with these above HLA alleles showed increased cytotoxic ability compared to those of control patients [[58]]. In contrast, data from Kuwaiti children with JIA showed an association with HLA-DRB1*0307 and HLA-DRB1*0308, indicating that HLA allelic associations may differ between ethnic groups [[59]].

Rheumatoid arthritis appears to be associated with HLA-DRB1 alleles which contain the QKRAA amino acid sequence [[60],[61]]. In fact, humoral and cellular immune responses are triggered in early rheumatoid arthritis patients with these HLA-alleles when stimulated with microbial antigens that share this QKRAA sequence, such as the dnaJ class of heat shock proteins from Escherichia coli, Brucella ovis, Lactobacillus lactis, and Epstein-Barr virus [[62],[63]]. While the HLA-DRB1 alleles and the frequency of these shared epitopes may vary between different ethnic groups, genotype does not necessarily correlate to disease severity, reflecting that factors besides genetics influence disease severity in rheumatoid arthritis [[64]]. In addition, data from monozygotic twins shows a concordance rate between 12 and 20% suggesting that environmental factors have substantial involvement in the development of rheumatoid arthritis [[65]]. The most consistently reported occupational exposure associated with rheumatoid arthritis is silica [[66]]. In addition, mineral oil, which acts as an adjuvant and induces arthritis in mice, has been suggested as a risk factor, although no human data exists [[67]].

Therefore, it appears that while there may be genetic predispositions to autoimmune diseases, disease incidence and severity is also shaped by the host’s immune response and environmental factors. A better understanding of response to cross-reactive self-epitopes and genetic factors, as well as their links to disease severity, will help target therapies in the future.

Targeted Therapy in Autoimmune Diseases

Current therapy for many autoimmune diseases is non-specifically aimed at decreasing the inflammatory cascade. This approach can lead to deleterious side effects, including osteoporosis, infection, and immunodeficiencies. Therapy directed at a specific part of the inflammatory cascade, such as anti-TNFα antibody, has shown promise by restoring the capacity of regulatory T cells to inhibit cytokine production, although CD4⁺CD25^bright cells that are most closely identified with regulation did not demonstrate this inhibition [[68]] (Table 2). However, even such targeted therapy has shown that TNFα is critical for protective immunity against infectious agents, and that anti-TNFα therapy can lead to higher incidence of Mycobacterium tuberculosis infection [[69],[70]]. A better form of therapy would be one that aims to control the immune response more specifically, enhancing the mechanisms of central and peripheral T cell tolerance that naturally exist to prevent autoimmunity. One such example would be epitope-specific immunotherapy that aims to create tolerance to self-epitopes involved in a specific autoimmune disease.

In terms of how to best induce tolerance, previous work has demonstrated that oral consumption of a potent nonself antigen by humans can lead to systemic T cell tolerance, reducing T cell proliferation compared to controls when challenged with the same antigen by subcutaneous immunization [[71]]. As occurs naturally, experimental animal models have shown that higher doses of antigen favor anergy or deletion [[72]]. Conversely, it is thought that low doses of orally or mucosally administered antigens induce production of regulatory T cells from the gut-associated lymphoid tissue, which then migrate to the systemic immune system [[73]]. In fact, recent data in mice demonstrate that colonic CD4⁺CD25⁺ T cells are necessary in order to prevent an inflammatory response to enteric antigens [[74]]. Furthermore, animal experiments have shown that oral administration of a self-antigen leads to suppression of an autoimmune disease, as is seen in depletion of peripheral antigen-specific T cells in mice after oral administration of myelin basic protein, protecting the mice from experimental autoimmune encephalomyelitis [[75]].

The ideal antigen for epitope-specific therapy would be one that has strong antigenic potential, induces regulatory cytokines, is available at the site of inflammation, and is conserved across species so as to treat diseases involving molecular mimicry. One class of proteins that appears to fill these criteria are heat shock proteins (hsp), which are evolutionarily conserved proteins present in prokaryotic and eukaryotic cellular organisms that are upregulated by stress [[76]].

Hsps, denoted by their weight in kilodaltons such as hsp60 or hsp70, have immunomodulatory properties both at the innate and adaptive immune response levels. In innate defense, human hsp60 has been shown to stimulate mouse macrophages to release the proinflammatory cytokine TNFα, which serves as a danger signal [[77]]. Further studies have shown that the proinflammatory response from several hsps are mediated through the innate immune Toll-like receptors, specifically TLR2 for chlamydial hsp60, and TLR2 and TLR4 for human hsp70 [[78],[79]].

Despite this proinflammatory pathway activation in innate immunity, experimental autoimmune models have shown repeatedly that immunization with hsp antigens leads to resistance rather than autoimmune disease, as would be expected. For example, in rat adjuvant arthritis, immunization with self hsp60 or hsp65 was found to be protective against development of autoimmune arthritis [[80],[81]]. Nasal administration of mycobacterial hsp65 and hsp70 peptides homologous to rat hsp sequences induced cross-reactive T cells that produced the inhibitory cytokine interleukin-10 (IL-10) [[82],[83]]. These data are, therefore, consistent with a regulatory T cell activation by the adaptive immune response after hsp stimulation.

In children with remitting oligoarticular JIA where a higher frequency of CD4⁺CD25⁺ cells were found in the synovial fluid, significant in vitro T cell responses to human hsp60 in peripheral blood mononuclear cells and synovial fluid correlated with earlier disease remission [[84],[85],[86]]. Similarly, mycobacterial hsp70 has been shown to induce IL-10-secreting synovial cells of arthritic patients with subsequent decrease in the proinflammatory cytokine TNFα [[87]]. These data imply that immune modulation with hsps may be an effective method of treatment in JIA or rheumatoid arthritis.

In theory, one should be able to induce tolerance to proinflammatory epitopes or shift the immune system to produce regulatory T cells to self epitopes via bystander activation. This could be accomplished by presenting conserved, cross-reactive peptides via the mucosal route. Application of such a theory led to considering dnaJp1, an Escherichia coli hsp-derived peptide that includes the QKRAA sequence known to be cross-reactive in rheumatoid arthritis, as a possible epitope-specific immunotherapy for rheumatoid arthritis. A phase I/IIa trial showed this treatment to be safe, in addition to oral therapy with dnaJp1 reducing the IL-2, TNFα, interferon gamma proinflammatory-producing cells and replacing them with IL-10 and IL-4 anti-inflammatory-producing cells [[88]]. Further data revealed that the total number of dnaJp1-specific T cells did not change, whereas the expression of CD4⁺CD25⁺ cells increased [[89]]. This data suggests that epitope-specific immunotherapy does not change the number of peptide-specific T cells by clonal deletion, but rather transforms their function into a regulatory phenotype. A similar outcome has been reported with in vitro incubation of oligoarticular JIA patients’ T cells with human hsp dnaJ epitopes [[90]].

Another form of autoimmune therapy is geared towards interfering with the costimulatory pathway that is critical for activation of proinflammatory T cells. Most promising has been CTLA-4, which inhibits activated T cells by blocking the costimulatory molecule B7 on antigen presenting cells from binding to its T cell receptor. A murine model demonstrated that intraarticular injection of an adenovirus vector containing a gene that encoded for CTLA-4 immunoglobulin inhibited the development of collagen-induced arthritis [[91]]. The initial study in patients with rheumatoid arthritis showed that intravenous infusion of CTLA-4 immunoglobulin was well tolerated and that there was a trend towards clinical improvement [[92],[93]]

As these newer forms of therapy demonstrate, the goal in the treatment of autoimmune diseases is to use the knowledge of genetic and cellular inflammatory mechanisms to create targeted therapy that does not disrupt the protective effects of the immune system.

Summary

· Via mechanisms of pattern recognition and tolerance, the innate and adaptive immune systems strive to differentiate self from non-self.

· Peripheral tolerance is influenced by the presence of regulatory T cells that produce the anti-inflammatory cytokine, IL-10.

· Mechanisms that show a link between infectious pathogens and autoimmune diseases include molecular mimicry, epitope spreading, and bystander activation.

· Environmental and genetic factors, most notably HLA class II genotype, affect autoimmune disease predisposition.

· Newer mechanisms of autoimmune disease therapy include anti-TNFα antibody, epitope-specific immunotherapy, and CTLA-4.

· Epitope-specific immunotherapy with heat shock proteins demonstrates regulatory T cell activation by the adaptive immune system.

References

[1]. Moll H. Dendritic cells and host resistance to infection, Cell Microbiol 2003;5(8):493-500.

2. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages, Annu Rev Immunol 1999;17:593-623.

[3]. Brightbill HD et al. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science. 30 July 1999;285(5428): 732-6.

[4]. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003 Oct;16(4):637-46.

[5]. Netea MG, van der Graaf C, Van der Meer JWM, Kullberg BJ. Toll-like receptors and the host defense against microbial pathogens: bringing

specificity to the innate-immune response. J Leukoc Biol. 2004 May;75(5):749-55.

[6]. Alam SM, Travers PJ, Wung JL, Nasholds W, Redpath S, Jameson SC, Gascoigne NRJ. T-cell receptor affinity and thymocyte positive selection.

Nature 1996;381(6583):616-20.

[7]. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003;21:139-76.

[8]. Oldstone MB, Molecular mimicry and autoimmune disease. Cell. 1987 Sep 11;50:819-20.

[9]. Walker LSK, Abbas AK. The enemy within: keeping self-reactive cells at bay in the periphery. Nat Rev Immunol. 2002 Jan;2(1):11-19.

[10]. Garcia KC, Degano M, Pease LR, Huang M, Peterson PA, Teyton L, Wilson IA. Structural basis of plasticity in T cell receptor recognition of a self

peptide-MHC antigen. Science. 1998 Feb 20;279(5354):1166-72.

[11]. Bonnin D, Prakken B, Samodal R, La Cava A, Carson DA, Albani S. Ontogeny of synonymous T cell populations with specificity for a self MHC

epitope mimicked by a bacterial homologue: an antigen-specific T cell analysis in a non-transgenic system. Eur J Immunol. 1999 Dec;29(12):3826-

36.

[12]. Semana G, Gausling R, Jackson RA, Hafler DA. T cell autoreactivity to proinsulin epitopes in diabetic patients and healthy subjects. J Autoimmun

1999;12(4):259-67.

[13]. Kurts C et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12703-7.

[14]. Alferink J, Tafuri An, Vestweber D, Hallmann R, Hammerling GJ, Arnold B. Control of neonatal tolerance to tissue antigens by peripheral T cell

trafficking. Science. 1998 Nov 13;282(5392):1338-41.

[15]. Alderson MR et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995 Jan 1;181(1):71-77.

[16]. Ahang J, Bardos T, Mikecz K, Finnegan Al, Gland TT. Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune

murine arthritis. J Immunol. 2001 Apr 15;166(8):4981-6.

[17]. Perez VL, Parijs LV, Biuckians A, Zhena XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997 Apr;6(4):411-7.

[18]. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996 Aug 1;184(2):387-96.

[19]. de Kleer IM et al. CD4⁺CD25^bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004;172:6435-43.

[20]. Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C. Isolation and functional characterization of regulatory CD25^bright CD4⁺ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol. 2003 Jan;33:215-223.

[21]. Malkiel S, Liao L, Cunningham MW, Diamond B. T-Cell-dependent antibody response to the dominant epitope of streptococcal polysaccharide, N-acetyl-glucosamine, is cross-reactive with cardiac myosin. Infect Immun. 2000 Oct;68(10):5803-8.

[22]. Quinn A, Kosanke S, Fischetti VA, Factor SM, Cunningham MW. Induction of autoimmune valvular heart disease by recombinant streptococcal m protein.Infect Immun. 2001 Jun; 69 (6):4072-8.

[23]. Guilherme L et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun. 2001 Sep;69(9):5345-51.

[24]. Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front Biosci. 2003 May 1;8:s533-43.

[25]. Guilherme L, Kalil J. Rheumatic fever: from sore throat to autoimmune heart lesions. Int Arch Allergy Immunol. 2004 May;134(1):56-64.

[26]. Panoutsakopoulou V, et al. Analysis of the relationship between viral infection and autoimmune disease. Immunity. 2001 Jul;15(1):137-47.

[27]. Zhao Z, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science. 1998 Feb ;279(5355):1344-7.

[28]. Honeyman MC et al. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes. 2000 Aug;49(8):1319-24.

[29]. Roep BO, Hiemstra HS, Schloot NC, De Vries RRP, Chaudhuri A, Behan PO, Drijfhout JW. Molecular mimicry in type 1 diabetes: immune cross-reactivity between islet autoantigen and human cytomegalovirus but not Coxsackie virus. Ann N Y Acad Sci. 2002 Apr;958:163-5.

[30]. Bachmaier K, Neu N, de la Maza L, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science. 1999 Feb 26;283(5406):1335-9.

[31]. Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. T cell recognition as the target for immune intervention in autoimmune disease. Cell. 1989 Jun 2;57(5):709-15.

[32]. Gautam AM, Yang M, Milburn PJ, Baker R, Bhatnagar A, McCluskey J, Boston T. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner. J Immunol. 1997 Sep 15;159(6):2782-8.

[33]. Albani S et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med. 1995 May;1(5):448-52.

[34]. Massa M et al. Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum. 2002 Oct;46(10):2721-9.

[35]. Martini A, Ravelli A, Albani S, Viola S, Scotta MS, Magrini U, Burgio GR. Recurrent juvenile dermatomyositis and cutaneous necrotizing arteritis with molecular mimicry between streptococcal type 5 M protein and human skeletal myosin. J Pediatr. 1992 Nov;121(5 Pt 1):739-42.

[36]. Albani S et al. Identification of cross-reactive epitopes on human skeletal myosin and streptococcal M5 protein in patients with juvenile dermatomyositis. Arthritis Rheum 1997;40:S140.

[37]. Wargula JC. Update on juvenile dermatomyositis: new advances in understanding its etiopathogenesis. Curr Opin Rheumatol 2003;15:595-601.

[38]. Massa M et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 2002 Nov;46(11):3015-25.

[39]. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002 Feb;2(2):85-95

[40]. Gerety SJ, Karpus WJ, Cubbon AR, Goswami RG, Rundell MK, Peterson JD, Miller SD. Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus-induced demyelinating disease. V. Mapping of a dominant immunopathologic VP2 T cell epitope in susceptible SJL/J mice. J Immunol. 1994 Jan 15;152(2):908-18.

[41]. Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, Neville KL, Katz-Levy Y, Carrizosa A, Kim BS. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med. 1997 Oct;3(10):1133-6.

[42]. Benoist C, Mathis D.Autoimmunity. The pathogen connection. Nature. 1998 Jul 16;394(6690):227-8.

[43]. von Herrath MG, Fujinami RS, Whitton JL. Microorganisms and autoimmunity: making the barren field fertile? Nat Rev Microbiol. 2003 Nov;1(2):151-7.

[44]. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med. 1998 Jul;4(7):781-5.

[45]. Zavattari P et al. Conditional linkage disequilibrium analysis of a complex disease superlocus, IDDM1 in the HLA region, reveals the presence of independent modifying gene effects influencing the type 1 diabetes risk encoded by the major HLA-DQB1, -DRB1 disease loci. Hum Mol Genet.2001 Dec 1;10(25):2907-16.

[46]. Lambert AP, Gillespie KM, Thomson G, Cordell HJ, Todd JA, Gale EAM, Bingley PJ. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab. 2004 Aug;89(8):4037-43.

[47]. Dorman JS, LaPorte RE, Stone RA, Trucco M. Worldwide differences in the incidence of type 1 diabetes are associated with amino acid variation at position 57 of the HLA-DQ β chain. Proc Natl Acad Sci. 1990 Oct;87(19):7370-4.

[48]. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes. 2003 Apr;52:1052-1055.

[49]. Kuman D et al. North-American twins with IDDM: genetic, etiological and clinical significance of disease concordance according to age, zygosity, and the interval after diagnosis in first twin. Diabetes. 1993 Sep:42(9):1351-63.

[50]. Clements GB, Galbraith DN, Taylor KW. Coxsackie B virus infection and onset of childhood diabetes. Lancet. 1995 Jul 22:346(8969):221-3.

[51]. Horwitz MS, Ilic A, Fine C, Balasa B, Sarvetnick N. Coxsackie viral-mediated diabetes: induction requires antigen-presenting cells and is accompanied by phagocytosis of beta cells. Clin Immunol. 2004 Feb:110(2):134-144.

[52]. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab Res Rev. 2003 Jan-Feb;19(1):8-31.

[53]. Hillebrands JL, van der Werf N, Klatter FA, Bruggeman CA, Rozing J. Role of peritoneal macrophages in cytomegalovirus-induced acceleration of autoimmune diabetes in BB-rats. Clin Dev Immunol. 2003 Jun-Dec;10(2-4):133-9.

[54]. Szkudelski T. The mechanism of alloxan and streptozotocin action in β cells of the rat pancreas. Physiol Res 2001. 50:536-546.

[55]. Yoon JW. The role of viruses and environmental factors in the induction of diabetes. Curr Top Microbiol Immunol 1990;164:95-123.

[56]. Albert ED, Scholz S. Juvenile arthritis: genetic update. Baillieres Clin Rheumatol. 1998 May;12(2):209-18.

[57]. Thomson W et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology 2002;41:1183-89.

[58]. Massa et al. Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum. 2002 Oct;46(10):2721-9.

[59]. Alsaeid KM, Haider MZ, al-Awadhi AM, Srivastva BS, Ayoub EM. Role of human leukocyte antigen DRB1*0307 and DRB1*0308 in susceptibility to juvenile rheumatoid arthritis. Clin Exp Rheumatol. 2003 May-Jun;21(3):399-402.

[60]. Ollier W, Thomson W. Population genetics of rheumatoid arthritis. Rheum Dis Clin North Am. 1992 Nov;18(4):741-59.

[61]. Albani S, Carson DA, Roudier J. Genetic and environmental factors in the immune pathogenesis of rheumatoid arthritis. Rheum Dis Clin North Am. 1992 Nov;18(4):729-40.

[62]. Albani S, Tuckwell JE, Esparza L, Carson DA, Roudier J. The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaJ and the histocompatibility leukocyte antigen DRB10401 molecule. J Clin Invest. 1992 Jan;89:327-331.

[63]. La Cava A et al. Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. J Clin Invest. 1997 Aug;100(3), 658-63.

[64]. del Rincon I, Battafarano DF, Arroyo RA, Murphy FT, Fischbach M, Escalante A. Ethnic variation in the clinical manifestations of rheumatoid arthritis: role of HLA-DRB1 alleles. Arthritis Rheum. 2003 Apr 15;49(2):200-8.

[65]. Malmstrom V, Trollmo C, Klareskog L. The additive role of innate and adaptive immunity in the development of arthritis. Am J Med Sci 2004;327(4):196-201.

[66]. Olsson AR, Skogh T, Axelson O, Wingren G. Occupations and exposures in the work environment as determinants for rheumatoid arthritis. Occup Environ Med 2004;61:233-38.

[67]. Kleinau S, Erlandsson H, Klareskog L. Percutaneous exposure of adjuvant oil causes arthritis in DA rats. Clin Exp Immunol. 1994 May;96(2):281-4.

[68]. Ehrenstein MR, Evans JG, Singh A, Moore S, Warners G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med. 2004 Aug 2. 200(3):277-285.

[69]. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents for tumor necrosis factor-alpha: California 2002-2003. MMWR Morb Mortal Wkly Rep. 2004 Aug 6;53:683-6.

[70]. Saunders BM, Briscoe H, Britton WJ. T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin Exp Immunol 2004;137:279-87.

[71]. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CO. Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding. J Immunol. 1994;152:4663.

[72]. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis: evidence for clonal anergy. J Immunol 1991;147:2155-63.

[73]. Toussirot EA. Oral tolerance in the treatment of rheumatoid arthritis. Curr Drug Targets Inflamm Allergy. 2002 Mar;1(1):45-52.

[74]. Gad M, Pedersen AE, Kristensen NN, Claesson MH. Demonstration of strong enterobacterial reactivity of CD4⁺CD25^- T cells from conventional and germ-free mice which is counter-regulated by CD4⁺CD25⁺ T cells. Eur J Immunol 2004;34:695-704.

[75]. Meyer AL et al. Rapid depletion of peripheral antigen-specific T cells in TCR-transgenic mice after oral administration of myelin basic protein. J Immunol 2001;166:5773-82.

[76]. van Eden W, Koets A, van Kooten P, Prakken B, van der Zee R. Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 2003;23:897-901.

[77]. Chen W, Syldath U, Bellmann K, Burkart V, Kolb H. Human 60-kda heat shock protein: a danger signal to the innate immune system. J Immunol 1999;162:3212-9.

[78]. Bulut Y et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002;168:1435-40.

[79]. Vabulast RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. Hsp70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem. 2002 Apr; 277(17):15107-12.

[80]. Anderton SM, van der Zee R, Prakken B, Noordzij A, van Eden W. Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis. J Exp Med. 1995 Mar;181:943-52.

[81]. Durai M, Gupta RS, Moudgil KD. The T cells specific for the carboxyl-terminal determinants of self (rat) heat shock protein 65 escape tolerance induction and are involved in regulation of autoimmune arthritis. J Immunol 2004;172:2795-802.

[82]. Prakken BJ, Roord S, Ronaghy A, Wauben M, Albani S, van Eden W. Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis. Springer Semin Immunopathnol 2003;25:47-63.

[83]. Wendling U, Paul L, van der Zee R, Prakken B, Singh M, van Eden W. A conserved mycobacterial heat shock protein 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp 70 homologue. J Immunol 2000;164:2711-17.

[84]. Prakken AB et al. Autoreactivity to human heat shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. Arthritis Rheum. 1996 Nov;39(11):1826-32.

[85]. Prakken B, Kuis W, van Eden W, Albani S. Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr Rheumatol Rep. 2002 Dec;4(6):466-73.

[86]. Graeff-Meeder ER et al. Juvenile chronic arthritis: T cell reactivity to human hsp60 in patients with a favorable course of arthritis. J Clin Invest 1995;95:934-40.

[87]. Detanico T, Rodrigues L, Sabritto AC, Keisermann M, Bauer ME, Zwickey H, Bonorino C. Mycobacterial heat shock protein 70 induces interleukin-10 production: immunomodulation of synovial cell cytokine profile and dendrites cell maturation. Clin Exp Immunol 2004:135:336-342.

[88]. Puga Yung GL, Le TD, Roord S, Prakken B, Albani S. Heat shock proteins for immunotherapy of rheumatoid arthritis. Inflamm Res 2003;52:443-51.

[89]. Prakken et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. 2004 Mar 23;101(12):4228-33.

[90]. Massa et al. Differential recognition of human and bacterial heat shock protein epitopes contribute to modulation of inflammation in oligoarticular juvenile idiopathic arthritis. Unpublished.

[91]. Ijima K et al. Successful gene therapy via intraarticular injection of adenovirus vector containing CTLA-4 IgG in a murine model of type II collagen-induced arthritis. Human Gene Therapy 2004;12:1063-77.

[92]. Liossis SN, Sfikakis PP. Costimulation in the treatment of rheumatic diseases. BioDrugs 2004;18(2):95-102.

[93]. Moreland LW et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46(6)1470-79.